| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced t...
Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced t...
Novanta (NASDAQ:NOVT) narrows FY2025 Adj EPS guidance from $3.22-$3.36 to $3.24-$3.30 vs $3.26 analyst estimate. Narrows FY2025...
Novanta (NASDAQ:NOVT) is looking for Q4 Adj EPS of $0.87-$0.93 vs $0.94 analyst estimate. sees sales of $253.000 million-$257.0...
Novanta (NASDAQ:NOVT) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.82 by 6.49...
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment m...
Baird analyst Robert Mason maintains Novanta (NASDAQ:NOVT) with a Neutral and lowers the price target from $139 to $133.
Novanta (NASDAQ:NOVT) lowers FY2025 Adj EPS guidance from $3.35-$3.55 to $3.22-$3.36 vs $3.37 analyst estimate. Lowers FY2025 s...